% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Njavro:169361,
author = {Njavro, Jasenka and Vukicevic, Marija and Fiorini, Emma and
Dinkel, Lina and Müller, Stephan A and Berghofer, Anna and
Bordier, Chiara and Kozlov, Stanislav and Halle, Annett and
Buschmann, Katrin and Capell, Anja and Giudici, Camilla and
Willem, Michael and Feederle, Regina and Lichtenthaler,
Stefan F and Babolin, Chiara and Montanari, Paolo and
Pfeifer, Andrea and Kosco-Vilbois, Marie and Tahirovic,
Sabina},
title = {{B}eneficial {E}ffect of {ACI}-24 {V}accination on {A}β
{P}laque {P}athology and {M}icroglial {P}henotypes in an
{A}myloidosis {M}ouse {M}odel.},
journal = {Cells},
volume = {12},
number = {1},
issn = {2073-4409},
address = {Basel},
publisher = {MDPI},
reportid = {DZNE-2023-00136},
pages = {79},
year = {2022},
abstract = {Amyloid-β (Aβ) deposition is an initiating factor in
Alzheimer's disease (AD). Microglia are the brain immune
cells that surround and phagocytose Aβ plaques, but their
phagocytic capacity declines in AD. This is in agreement
with studies that associate AD risk loci with genes
regulating the phagocytic function of immune cells.
Immunotherapies are currently pursued as strategies against
AD and there are increased efforts to understand the role of
the immune system in ameliorating AD pathology. Here, we
evaluated the effect of the Aβ targeting ACI-24 vaccine in
reducing AD pathology in an amyloidosis mouse model. ACI-24
vaccination elicited a robust and sustained antibody
response in APPPS1 mice with an accompanying reduction of
Aβ plaque load, Aβ plaque-associated ApoE and dystrophic
neurites as compared to non-vaccinated controls.
Furthermore, an increased number of NLRP3-positive
plaque-associated microglia was observed following ACI-24
vaccination. In contrast to this local microglial activation
at Aβ plaques, we observed a more ramified morphology of
Aβ plaque-distant microglia compared to non-vaccinated
controls. Accordingly, bulk transcriptomic analysis revealed
a trend towards the reduced expression of several
disease-associated microglia (DAM) signatures that is in
line with the reduced Aβ plaque load triggered by ACI-24
vaccination. Our study demonstrates that administration of
the Aβ targeting vaccine ACI-24 reduces AD pathology,
suggesting its use as a safe and cost-effective AD
therapeutic intervention.},
keywords = {Mice / Animals / Microglia: metabolism / Amyloid
beta-Protein Precursor: metabolism / Mice, Transgenic /
Amyloid beta-Peptides: metabolism / Alzheimer Disease:
genetics / Alzheimer Disease: therapy / Alzheimer Disease:
metabolism / Amyloidosis: metabolism / Plaque, Amyloid:
metabolism / Phenotype / Vaccination / Alzheimer’s disease
(Other) / ACI-24 (Other) / Alzheimer’s disease (Other) /
Aβ vaccine (Other) / immunotherapy (Other) / microglia
(Other) / Amyloid beta-Protein Precursor (NLM Chemicals) /
Amyloid beta-Peptides (NLM Chemicals) / Aβ vaccine (Other)},
cin = {AG Tahirovic / AG Lichtenthaler / AG Halle / AG Haass old},
ddc = {570},
cid = {I:(DE-2719)1140003 / I:(DE-2719)1110006 /
I:(DE-2719)1013034 / I:(DE-2719)1110007},
pnm = {352 - Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36611872},
pmc = {pmc:PMC9818422},
doi = {10.3390/cells12010079},
url = {https://pub.dzne.de/record/169361},
}